Primary Burning Mouth Syndrome
Conditions
Keywords
Primary Burning Mouth Syndrome, Salivary metabolomic
Brief summary
Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially postmenopausal women. Its physiopathology is still unknown and several hypotheses have been put forward to explain this syndrome, such as neurological, hormonal or inflammatory process. The recent development of salivary metabolomic profiling in oral diseases has led to the identification of potential pathways in such disorders. The aim of this study is to analyze the salivary metabolomic in BMS patients compared to healthy controls.
Detailed description
Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially postmenopausal women. Its physiopathology is still unknown and several hypotheses have been put forward to explain this syndrome, such as neurological, hormonal or inflammatory process. The recent development of salivary metabolomic profiling in oral diseases has led to the identification of potential pathways in such disorders. The aim of this study is to analyze the salivary metabolomic in BMS patients compared to healthy controls.
Interventions
OTHERSalivic sample
Collection of total saliva not stimulated
Sponsors
University Hospital, Tours
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* For cases : primary Burning Mouth Syndrome, based on the IHS diagnosis criteria * For cases : being able to realise the salivary collection * For controls : no primary BMS * For controls : being able to realise the salivary collection
Exclusion criteria
for both groups: * Treatment by antibiotics in the previous month * New treatment in the previous two weeks * Active smoking * Active infectious or inflammatory oral disease * Systemic disease that could have an impact on the salivary metabolome or on the neurological system * Being under legal guardianship * Opposition to the processing of personal data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparative analysis of salivary metabolomic profiles between cases (primary BMS) and controls | at inclusion | metabolites will be measured in saliva by chromatography-mass spectrometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparative analysis of salivary neuropeptides between cases (primary BMS) and controls | at inclusion | quantitative assessment of levels of neuropeptides (NGF, histamine, tryptase, kallicrein) will be assessed in saliva in cases and controls |
| Comparative analysis of salivary hormones between cases (primary BMS) and controls | at inclusion | quantitative assessment of levels of steroid hormones (cortisol, 11-desoxycortisol, DHEA, SDHEA, progesterone, 17-hydroxyprogesterone, testosterone, androstenedione) will be assessed in saliva in cases and controls |
| Comparative analysis of salivary inflammatory cytokines between cases (primary BMS) and controls | at inclusion | quantitative assessment of levels of cytokines (IL-2, IL-6, IL-18, TNFα) will be assessed in saliva in cases and controls |
| Correlation between salivary biomarkers and pain characteristics | at inclusion | metabolites profile, salivary neuropeptides, hormones and cytokines will be compared according to the category of pain (type I-II-III, neuropathic pain score DN4\>4) |
Countries
France
Outcome results
None listed